Your browser doesn't support javascript.
loading
Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response.
Spencer, Christine N; McQuade, Jennifer L; Gopalakrishnan, Vancheswaran; McCulloch, John A; Vetizou, Marie; Cogdill, Alexandria P; Khan, Md A Wadud; Zhang, Xiaotao; White, Michael G; Peterson, Christine B; Wong, Matthew C; Morad, Golnaz; Rodgers, Theresa; Badger, Jonathan H; Helmink, Beth A; Andrews, Miles C; Rodrigues, Richard R; Morgun, Andrey; Kim, Young S; Roszik, Jason; Hoffman, Kristi L; Zheng, Jiali; Zhou, Yifan; Medik, Yusra B; Kahn, Laura M; Johnson, Sarah; Hudgens, Courtney W; Wani, Khalida; Gaudreau, Pierre-Olivier; Harris, Angela L; Jamal, Mohamed A; Baruch, Erez N; Perez-Guijarro, Eva; Day, Chi-Ping; Merlino, Glenn; Pazdrak, Barbara; Lochmann, Brooke S; Szczepaniak-Sloane, Robert A; Arora, Reetakshi; Anderson, Jaime; Zobniw, Chrystia M; Posada, Eliza; Sirmans, Elizabeth; Simon, Julie; Haydu, Lauren E; Burton, Elizabeth M; Wang, Linghua; Dang, Minghao; Clise-Dwyer, Karen; Schneider, Sarah.
Afiliação
  • Spencer CN; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • McQuade JL; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Gopalakrishnan V; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • McCulloch JA; Laboratory of Integrative Cancer Immunology, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892, USA.
  • Vetizou M; Laboratory of Integrative Cancer Immunology, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892, USA.
  • Cogdill AP; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Khan MAW; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Zhang X; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • White MG; Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Peterson CB; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Wong MC; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Morad G; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Rodgers T; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Badger JH; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Helmink BA; Laboratory of Integrative Cancer Immunology, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892, USA.
  • Andrews MC; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Rodrigues RR; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Morgun A; Department of Medicine, Monash University, Melbourne, VIC 3004, Australia.
  • Kim YS; Frederick National Laboratory for Cancer Research, and Microbiome and Genetics Core, Laboratory of Integrative Cancer Immunology, CCR, NCI, NIH, Bethesda, MD 20852, USA.
  • Roszik J; Department of Pharmaceutical Science, Oregon State University, Corvallis, OR 97331, USA.
  • Hoffman KL; Nutritional Science Research Group, Division of Cancer Prevention, NCI, NIH, Rockville, MD 20850, USA.
  • Zheng J; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Zhou Y; Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA.
  • Medik YB; Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Kahn LM; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Johnson S; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Hudgens CW; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Wani K; MD Anderson University of Texas Health Graduate School, Houston, TX 77030, USA.
  • Gaudreau PO; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Harris AL; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Jamal MA; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Baruch EN; Canadian Cancer Trials Group and Department of Oncology, Queen's University, Kingston, ON K7L 3N6, Canada.
  • Perez-Guijarro E; Center for Co-Clinical Trials, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Day CP; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Merlino G; Department of Internal Medicine, The University of Texas Health Science Center, Houston, TX 77030, USA.
  • Pazdrak B; Laboratory of Cancer Biology and Genetics, CCR, NCI, NIH, Bethesda, MD 20892, USA.
  • Lochmann BS; Laboratory of Cancer Biology and Genetics, CCR, NCI, NIH, Bethesda, MD 20892, USA.
  • Szczepaniak-Sloane RA; Laboratory of Cancer Biology and Genetics, CCR, NCI, NIH, Bethesda, MD 20892, USA.
  • Arora R; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Anderson J; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Zobniw CM; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Posada E; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Sirmans E; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Simon J; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Haydu LE; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Burton EM; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Wang L; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Dang M; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Clise-Dwyer K; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Schneider S; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Science ; 374(6575): 1632-1640, 2021 Dec 24.
Article em En | MEDLINE | ID: mdl-34941392
ABSTRACT
Gut bacteria modulate the response to immune checkpoint blockade (ICB) treatment in cancer, but the effect of diet and supplements on this interaction is not well studied. We assessed fecal microbiota profiles, dietary habits, and commercially available probiotic supplement use in melanoma patients and performed parallel preclinical studies. Higher dietary fiber was associated with significantly improved progression-free survival in 128 patients on ICB, with the most pronounced benefit observed in patients with sufficient dietary fiber intake and no probiotic use. Findings were recapitulated in preclinical models, which demonstrated impaired treatment response to anti­programmed cell death 1 (anti­PD-1)­based therapy in mice receiving a low-fiber diet or probiotics, with a lower frequency of interferon-γ­positive cytotoxic T cells in the tumor microenvironment. Together, these data have clinical implications for patients receiving ICB for cancer.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fibras na Dieta / Probióticos / Microbioma Gastrointestinal / Inibidores de Checkpoint Imunológico / Melanoma Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fibras na Dieta / Probióticos / Microbioma Gastrointestinal / Inibidores de Checkpoint Imunológico / Melanoma Idioma: En Ano de publicação: 2021 Tipo de documento: Article